Zahid Ahmad, MD
Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1053529099
Payments from drug & device makers
Across 81 payments — averaging $4119.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$251K
- Ionis Pharmaceuticals, Inc.$52K
- Amgen$26K
- Regeneron Healthcare Solutions, Inc.$2K
- Akcea Therapeutics, Inc.$2K
- Chiesi USA, Inc.$625
Across 6 payments — averaging $1234.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiesi USA, Inc.$6K
- Regeneron$1K
What the payments were for
- Consulting fees$4,17087%
- Speaking & faculty fees$62513%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 66 | $250,619 |
| Ionis Pharmaceuticals, Inc. | 8 | $51,979 |
| Amgen | 3 | $26,400 |
| Regeneron Healthcare Solutions, Inc. | 1 | $2,140 |
| Akcea Therapeutics, Inc. | 1 | $1,880 |
| Chiesi USA, Inc. | 2 | $625 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$333,643 in reported general payments places this provider in the 85th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 206 | $156,204 |
| Praluent PenAlirocumab | 104 | $57,183 |
| OzempicSemaglutide | 28 | $40,666 |
| VascepaIcosapent Ethyl | 41 | $21,777 |
| Repatha SyringeEvolocumab | 12 | $8,750 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 17 | $2,789 |
| Ezetimibe | 130 | $2,653 |
| Omega-3 Acid Ethyl Esters | 16 | $1,142 |
| Rosuvastatin Calcium | 96 | $629 |
| FenofibrateFenofibrate,micronized | 12 | $465 |
| Atorvastatin Calcium | 35 | $248 |
| Pravastatin Sodium | 24 | $200 |
| Gemfibrozil | 11 | $98 |
| Metformin Hcl | 16 | $66 |
| Methimazole | 11 | $33 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Dallas
- Julio RosenstockDallas$24.9M
- Ildiko LingvayDallas$8.2M
- Peter BresslerDallas$4.2M
- Steve FordanDallas$2.8M
- Pablo MoraDallas$2.1M
- Saleemah FahmiDallas$1.2M
- Priscilla HollanderDallas$1M
- Oksana HamidiDallas$1M
- Amy ShahDallas$953K
- Abhimanyu GargDallas$920K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.